New York, USA, May 05, 2026 (GLOBE NEWSWIRE) — Global Stem Cell Therapy Market Set to Flourish at a CAGR of ~11% by 2034 Owing to the Technological Advancements and Favorable Regulations | DelveInsight

The stem cell therapy market is witnessing strong growth driven by rising demand for regenerative medicine and advanced treatment options for chronic diseases such as cancer, diabetes, and neurological disorders. Increasing investments in research, clinical trials, and biotechnology innovation are accelerating the development of new stem cell-based therapies. Supportive regulatory frameworks and growing adoption of personalized medicine are further boosting market expansion.

DelveInsight’s Stem Cell Therapy Market Insights report provides the current and forecast market analysis, individual leading stem cell therapy companies’ market shares, challenges, stem cell therapy market drivers, barriers, trends, and key stem cell therapy companies in the market.

Stem Cell Therapy Market Summary

• 2025 Stem Cell Therapy Market Size: USD 21.9 Billion
• 2034 Projected Stem Cell Therapy Market Size: USD 58.5 Billion
• Stem Cell Therapy Market Growth Rate (2026-2034): ~11% 
• Largest Stem Cell Therapy Market: North America
• Largest Therapy Type Segment: Allogenic Category
• Key Companies in the Stem Cell Therapy Market: New York Blood Center, Cleveland Cord Blood Center, Duke University, Takeda Pharmaceutical Company, JCR Pharmaceuticals, Medipost, Stempeutics Research, Nipro Corporation, Vericel Corporation, Holostem Terapie Avanzate, Orchard Therapeutics, Bluebird Bio, Cynata Therapeutics, Sumitomo Pharma Co., Ltd., and others

To read more about the latest highlights related to the stem cell therapy market, get a snapshot of the key highlights @  https://www.delveinsight.com/sample-request/stem-cell-market

Key Factors Contributing to the Rise in Growth of the Stem Cell Therapy Market

• Increasing Prevalence of Chronic and Degenerative Diseases: Rising cases of conditions such as cancer, diabetes, cardiovascular disorders, neurological diseases, and autoimmune disorders are driving demand for regenerative treatment options like stem cell therapy.
• Advancements in Regenerative Medicine Research: Continuous progress in stem cell biology, gene editing, tissue engineering, and cell expansion technologies has improved the safety, efficacy, and scalability of stem cell therapies.
• Growing Clinical Trial Activity: A significant increase in clinical studies evaluating stem cell-based treatments across multiple therapeutic areas is accelerating product development and market confidence.
• Supportive Regulatory Frameworks: Favorable government initiatives, expedited approval pathways, and increasing regulatory support for regenerative medicines in countries such as Japan, the United States, and South Korea are boosting commercialization.
• Rising Investments and Funding: Increased investments from biotech companies, pharmaceutical firms, venture capitalists, and public organizations are supporting innovation and manufacturing expansion.
• Growing Demand for Personalized Medicine: Stem cell therapies offer patient-specific treatment approaches, making them attractive in precision medicine and targeted healthcare strategies.
• Expanding Applications Across Therapeutic Areas: Beyond oncology, stem cell therapies are gaining traction in orthopedics, dermatology, ophthalmology, cardiology, and neurology, broadening market opportunities.
• Improved Manufacturing and Storage Infrastructure: Advances in cell banking, cryopreservation, and large-scale manufacturing processes are making stem cell products more accessible and commercially viable.
• Rising Awareness and Acceptance: Increasing awareness among healthcare professionals and patients regarding the potential of stem cell therapies is supporting adoption globally.

Get a sneak peek at the stem cell therapy market dynamics @ Stem Cell Therapy Market Trends

Regional Stem Cell Therapy Market Insights

North America

• Among all regions, North America held the largest share of the stem cell market in 2025, accounting for 48.87%. 
• The region is anticipated to lead the market owing to its advanced healthcare infrastructure, substantial investments in regenerative medicine, and a significant number of ongoing clinical trials and product approvals. 
• Moreover, the rising burden of chronic diseases, strong presence of renowned research institutions, and leading industry participants further support the early adoption and commercialization of innovative stem cell therapies across the region.

Europe

• Europe’s stem cell market is witnessing significant expansion, supported by favorable regulatory policies, rising public and private funding, and ongoing progress in regenerative medicine. 
• The region benefits from a structured regulatory pathway established by the European Medicines Agency for Advanced Therapy Medicinal Products (ATMPs), enabling faster development and market entry of stem cell therapies. 
• In addition, growing partnerships among academic institutions, biotechnology firms, and government organizations are encouraging innovation and strengthening the pipeline of stem cell-based treatments across areas such as ophthalmology, orthopedics, and rare diseases. 
• Together, these factors, including regulatory support, sustained R&D investments, key product approvals, and an increasing disease burden, are strongly contributing to the growth of the stem cell market in Europe.

Asia-Pacific

• The Asia Pacific region is becoming a key engine of growth for the Stem Cell Research market, supported by favorable government initiatives, faster clinical adoption, growing biotechnology capabilities, increasing healthcare spending, and a vast patient base with significant unmet medical needs. 
• Nations including China, Japan, South Korea, and India are leading efforts in advancing both stem cell research and commercial development. 
• Japan has especially strengthened its position through an accelerated approval pathway for regenerative medicine, driving major milestones such as the March 2026 conditional approval of iPSC-based therapies like ReHeart and Amusepri for heart failure and Parkinson’s disease, representing some of the first real-world uses of reprogrammed stem cell treatments globally.

To know more about why North America is leading the market growth in the stem cell therapy market, get a snapshot of the Stem Cell Therapy Market Share

Recent Developmental Activities in the Stem Cell Therapy Market

• In March 2026, Japan approved Amchepry, the world’s first regenerative medicine treatment using induced pluripotent stem (iPS) cells to treat Parkinson’s disease.
• In December 2025, Cipla Limited announced the launch of Ciplostem, an innovative allogeneic mesenchymal stromal cell (MSC) therapy for Knee Osteoarthritis (Knee OA), approved by the Drug Controller General of India (DCGI). Developed by Stempeutics Research, the therapy offers a disease-modifying treatment option targeting Grade II and III Knee OA and marks a significant advancement in Cipla’s entry into Orthobiologic medicine.
• In April 2025, an off-the-shelf, iPSC-derived CAR T-cell therapy for the treatment of active moderate to severe systemic lupus erythematosus (SLE), including lupus nephritis (LN), was granted an FDA RMAT designation for entering Phase I clinical trial.
• In February 2025, the FDA granted IND clearance for Fertilo (Figure 2), the first iPSC-based therapy to enter a U.S. Phase III trial.

What is Stem Cell Therapy?

Stem cell therapy is a form of regenerative medicine that uses stem cells to repair, replace, or regenerate damaged tissues and cells in the body. Stem cells are unique because they have the ability to develop into different specialized cell types, such as muscle cells, nerve cells, or blood cells, depending on the body’s needs. This therapy is being explored and used for treating a range of conditions, including blood disorders, certain cancers, orthopedic injuries, neurological diseases, and autoimmune disorders. Common sources of stem cells include bone marrow, adipose tissue, umbilical cord blood, and laboratory-grown pluripotent stem cells. Stem cell therapy aims to restore normal function, promote healing, and improve patient outcomes, making it a promising area of modern healthcare and biomedical research.

Stem Cell Therapy Market Assessment

• Stem Cell Therapy Market Segmentation
  • Stem Cell Therapy Market Segmentation By Therapy Type: Allogenic and Autologous
  • Stem Cell Therapy Market Segmentation By Cell Source: Adult Stem Cells {Hematopoietic Stem Cells (HSCs), Mesenchymal Stem Cells (MSCs), and Others}, Embryonic Stem Cells (ESCs), and Induced Pluripotent Stem Cells (iPSCs)
  • Stem Cell Therapy Market Segmentation By Therapeutic Application: Hematological Disorders, Musculoskeletal Disorders, Neurological Disorders, and Others
  • Stem Cell Therapy Market Segmentation By Technology: Cell Collection & Isolation, Cell Expansion & Culturing, Cryopreservation & Storage, and Others
  • Stem Cell Therapy Market Segmentation By End User: Hospitals & Transplant Centers, Academic & Research Institutes, and Others
  • Stem Cell Therapy Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Which MedTech key players in the stem cell therapy market are set to emerge as the trendsetter explore @ Stem Cell Therapy Market Analysis

Table of Contents 

Interested in knowing the stem cell therapy market share by 2034? Click to get a snapshot of the Stem Cell Therapy Market Size 

Related Reports

Hematopoietic Stem Cell Transplantation Market

Hematopoietic Stem Cell Transplantation Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key HSCT companies including Actinium Pharmaceuticals, Medexus Pharmaceuticals, medac Pharma, BioLineRx, Sanofi, and others.

Hematopoietic Stem Cell Transplantation Clinical Trial Analysis 

Hematopoietic Stem Cell Transplantation Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key HSCT companies, including Actinium Pharmaceuticals, BioLineRx, Athersys, Novartis, CareDex, Orchard Therapeutics, Magenta Therapeutics, Graphite Bio, Vor Biopharma, Jasper Therapeutics, Garuda Therapeutics, and others.

Allogeneic Hematopoietic Stem Cell Transplant Market

Allogeneic Hematopoietic Stem Cell Transplant Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key HSCT companies including Merck Sharp & Dohme LLC, In8bio Inc., Incyte Corporation, Forge Biologics, Inc, GlaxoSmithKline, Bellicum Pharmaceuticals, SecuraBio, ModernaTX, Inc., Miltenyi Biotec, Inc., Jazz Pharmaceuticals, Gilead Sciences, Celularity Incorporated, Seres Therapeutics, Inc., Omeros Corporation, Novartis, Marker Therapeutics, Inc., and others.

Multiple Myeloma Market

Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple myeloma companies, including  Johnson & Johnson (Janssen), Pfizer, AbbVie and Roche (Genentech), Regeneron Pharmaceuticals, Bristol-Myers Squibb, Celgene, Roche (Genentech), Arcellx, Novartis, Regeneron Pharmaceuticals, BeiGene, CARsgen Therapeutics, Cartesian Therapeutics, C4 Therapeutics, Heidelberg Pharma, Bristol-Myers Squibb, RAPA Therapeutics, AbbVie (TeneoOne), Takeda, and others.

Non-Hodgkin’s Lymphoma Market

Non-Hodgkin’s Lymphoma Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NHL companies, including Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc, Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd., Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

CONTACT: Contact Us Shruti Thakur  info@delveinsight.com  +14699457679

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.

New York, USA, May 05, 2026 (GLOBE NEWSWIRE) — Hemophilia Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

The hemophilia clinical trial analysis report delivers important insights into ongoing research of 55+ pipeline hemophilia drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

DelveInsight’s ‘Hemophilia Pipeline Insight 2026’ report provides comprehensive global coverage of pipeline therapies for hemophilia across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the hemophilia domain.

Hemophilia Clinical Trial Analysis Summary

• DelveInsight’s hemophilia pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline hemophilia drugs. 
• Key hemophilia companies, such as Novo Nordisk A/S, Suzhou Alphamab, Roche, Chugai Pharmaceutical Co., Ltd., Be Biopharma, Regeneron Pharmaceuticals, Intellia Therapeutics, Equilibra Bioscience, TiumBio, Metagenomi Therapeutics, Gritgen Therapeutics, Cabalettabio, Link Bio, GCBiopharma, Bayer, Jiangsu Gensciences lnc., Belief Biomed, Sernova, and others, are evaluating new hemophilia drugs to improve the treatment landscape.
• Promising pipeline hemophilia therapies, such as Denecimig, KN057, NXT007, BE-101, REGV131-LNP1265, SR604, TU7710, MGX 001, GS1191-0445, FVIII-CAART, LB02, MG1113A, BAY2599023, SS109, BBM H803, Haemophilia A allogenic cell therapy, and others, are in different phases of hemophilia clinical trials.
• Approximately 10+ hemophilia drugs are in the late and mid stages of development.
• Notable MoAs in hemophilia clinical trials include FVIII mimetic, Immunomodulators, Anti-FIXa/FX, Factor IX replacement, Factor IX replacement, Activated protein C inhibition, Blood coagulation factor modulator, Factor VII replacement, and others.

Request a sample and discover the recent advances in hemophilia drug development @ https://www.delveinsight.com/sample-request/hemophilia-pipeline-insight

What is Hemophilia?

Hemophilia is a rare inherited bleeding disorder in which the blood does not clot properly due to a deficiency or absence of specific clotting factors, most commonly factor VIII (Hemophilia A) or factor IX (Hemophilia B). Because of this defect, individuals with hemophilia may experience prolonged bleeding after injuries, surgeries, or even spontaneous internal bleeding, particularly into joints and muscles. The condition is typically caused by genetic mutations on the X chromosome, which is why it predominantly affects males, while females are usually carriers. Severity can vary depending on the level of clotting factor present, ranging from mild cases with bleeding only after major trauma to severe forms characterized by frequent spontaneous bleeding episodes. Modern treatments, including clotting factor replacement therapies and newer gene therapies, have significantly improved disease management and quality of life for patients.

Find out more about hemophilia drug development @ Hemophilia Treatment

A snapshot of the Pipeline Hemophilia Drugs mentioned in the report:

Learn more about the emerging hemophilia therapies @ Hemophilia Clinical Trials 

According to Stuti Mahajan, consulting manager at DelveInsight, the market is being driven by the growing uptake of advanced treatment options, particularly long-acting factor therapies and emerging gene therapies, which are helping patients manage the condition more effectively with fewer interventions. As these more convenient and potentially transformative therapies gain traction, they are steadily shaping growth in the hemophilia treatment landscape.

Recent Developments in Hemophilia Treatment Space

• In March 2026, Metagenomi Inc. provided an update on its MGX-001 program, announcing the successful completion of a pre-IND meeting and reaffirming its timeline to advance the global clinical program, with an IND submission planned for Q4 2026 and initiation of clinical trials in 2027, subject to regulatory clearance.
• In February 2026, Chugai Pharmaceutical Co., Ltd. announced that the data from Part C of the Phase I/II NXTAGE study, the first clinical data evaluating NXT007 in people switching from emicizumab without a washout period, were presented at the 2026 European Association for Haemophilia and Allied Disorders (EAHAD) Congress held in Ireland.
• In November 2025, Metagenomi Inc. announced new preclinical data for its hemophilia A gene-editing therapy MGX-001, demonstrating curative levels of factor VIII (FVIII) activity in non-human primates. The results support advancement of the program into clinical development. The company plans to conduct regulatory interactions and submit IND/CTA applications in 2026 to initiate first-in-human clinical trials.
• In September 2025, Novo Nordisk A/S submitted a Biologics License Application to the US FDA seeking approval for Mim8 (denecimig), an investigational subcutaneous prophylactic therapy for Hemophilia A with or without inhibitors. The application is supported by Phase III data showing a significant reduction in bleeding episodes, and the therapy is designed to offer flexible weekly to monthly dosing options.
• In July 2025, Be Biopharma, Inc announced the first participant was treated with BE-101 in the BeCoMe-9 Phase I/II clinical trial designed to assess the safety and preliminary efficacy of BE-101 in participants with moderately severe to severe hemophilia B.
• In May 2024, FDA granted Fast Track Designation (FTD) to SR604 for the routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with severe hemophilia A and severe hemophilia B with or without inhibitors.
• In December 2024, TiumBio announced the successful completion of its Phase Ia clinical trial of TU7710, a long-acting recombinant activated factor VII, along with positive Phase Ia results.

Scope of the Hemophilia Pipeline Report 

• Coverage: Global 
• Hemophilia Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Hemophilia Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Hemophilia Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal
• Hemophilia Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule
• Hemophilia Therapeutics Assessment By Mechanism of Action: FVIII mimetic, Immunomodulators, Anti-FIXa/FX, Factor IX replacement, Factor IX replacement, Activated protein C inhibition, Blood coagulation factor modulator, Factor VII replacement, and others
• Key Hemophilia Companies: Novo Nordisk A/S, Suzhou Alphamab, Roche, Chugai Pharmaceutical Co., Ltd., Be Biopharma, Regeneron Pharmaceuticals, Intellia Therapeutics, Equilibra Bioscience, TiumBio, Metagenomi Therapeutics, Gritgen Therapeutics, Cabalettabio, Link Bio, GCBiopharma, Bayer, Jiangsu Gensciences lnc., Belief Biomed, Sernova and others
• Key Hemophilia Pipeline Therapies: Denecimig, KN057, NXT007, BE-101, REGV131-LNP1265, SR604, TU7710, MGX 001, GS1191-0445, FVIII-CAART, LB02, MG1113A, BAY2599023, SS109, BBM H803, Haemophilia A allogenic cell therapy and others.

Dive deep into rich insights for new hemophilia treatments, visit @ Hemophilia Drugs

Table of Contents

For further information on the hemophilia cure research, reach out @ Medication for Hemophilia Treatment

Related Reports

Hemophilia Market

Hemophilia Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Hemophilia companies, including Roche (Genentech), Takeda, Novo Nordisk, Pfizer, CSL Behring, Bayer, Sanofi, BioMarin Pharmaceutical, and others.

Hemophilia A Market

Hemophilia A Market Size, Target Population, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key hemophilia A companies, including BioMarin Pharmaceutical, Roche (Spark Therapeutics), ApcinteX, Novo Nordisk, Sanofi (Genzyme), Alnylam Pharmaceuticals, Pfizer, Sangamo Therapeutics, Bayer, Ultragenyx Pharmaceutical, and others.

Hemophilia B Market

Hemophilia B Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hemophilia B companies, including Centessa Pharmaceuticals, Sanofi (Genzyme), Alnylam Pharmaceuticals, Pfizer, Spark Therapeutics, Be Biopharma, Equilibra Bioscience, Regeneron Pharmaceuticals, Intellia Therapeutics, Novo Nordisk, and others.

Multiple Myeloma Market

Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple myeloma companies, including Johnson & Johnson (Janssen), Pfizer, AbbVie and Roche (Genentech), Regeneron Pharmaceuticals, Bristol-Myers Squibb, Celgene, Roche (Genentech), Arcellx, Novartis, Regeneron Pharmaceuticals, BeiGene, CARsgen Therapeutics, Cartesian Therapeutics, C4 Therapeutics, Heidelberg Pharma, Bristol-Myers Squibb, RAPA Therapeutics, AbbVie (TeneoOne), Takeda, and others.

Sickle Cell Disease Market

Sickle Cell Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key sickle cell disease companies, including Vertex Pharmaceuticals, CRISPR Therapeutics, Bluebird Bio, Global Blood Therapeutics, Pfizer, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

CONTACT: Contact Us Shruti Thakur  info@delveinsight.com  +14699457679

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.

Austin, United States, May 05, 2026 (GLOBE NEWSWIRE) — “According to SNS Insider, the Coronary Artery Bypass Graft Market size was valued at USD 19.56 Billion in 2025 and is projected to reach USD 26.79 Billion by 2035, representing a Compound Annual Growth Rate (CAGR) of 3.22% during the forecast period.”

Coronary artery bypass graft (CABG) market is expected to grow steadily owing to the increase in the burden of coronary artery disease across the globe and need for reliable surgical revascularization procedures. Progress in graft materials, surgical tools, and robotic-assisted procedures are enhancing clinical outcomes and patient recovery. Moreover, factors such as the increasing incidence of lifestyle-associate disease such as diabetes, hypertension, and obesity is auguring well for the technique of CABG, particularly in the hospital settings with conducive infrastructure such as cardiac care units.

Get a Sample Report of Coronary Artery Bypass Graft Market: https://www.snsinsider.com/sample-request/10094

The U.S. Coronary Artery Bypass Graft Market is projected to grow from USD 6.40 Billion in 2025 to USD 8.27 Billion by 2035, at a CAGR of 2.62% during the forecast period of 2025–2035.

The US is the largest market in North America due to the high prevalence of coronary artery diseases, widespread acceptance of minimally invasive cardiac surgeries, and better availability of healthcare facilities. The presence of established cardiac centers, favorable reimbursement policies, and increasing elderly population will drive the demand for the market further.

Major Coronary Artery Bypass Graft Market Companies Listed in the Report are

• Medtronic plc
• Boston Scientific Corporation
• Abbott Laboratories
• Terumo Corporation
• Edwards Lifesciences Corporation
• Getinge AB
• LivaNova PLC
• B. Braun Melsungen AG
• Johnson & Johnson (Ethicon)
• W. L. Gore & Associates, Inc.
• Cardinal Health, Inc.
• Cook Medical Incorporated
• Teleflex Incorporated
• Zimmer Biomet Holdings, Inc.
• MicroPort Scientific Corporation
• Artivion, Inc.
• CryoLife, Inc.
• Maquet Holding B.V. & Co. KG
• Sorin Group (LivaNova legacy)
• Stryker Corporation

Segment Analysis

By Procedure / Technology Type, On-Pump CABG Segment Dominates the Coronary Artery Bypass Graft Market

On-Pump CABG accounted for the largest market share of 52.41% in 2025 as it is standardized, reliable and highly effective in managing complex multi-vessel coronary artery disease cases. This step offers a stable surgical field that makes these procedures the preferred approach for complex surgeries. On-Pump CABG procedures surpassed 830,000 worldwide in 2025, consolidating its position as the global leader.

Robotic-Assisted CABG is anticipated to record the fastest growth, specifically the highest CAGR of about 6.92% during the period 2026–2035, owing to rising demand for minimally invasive surgeries and better surgical precision and quicker patient recovery offered with further advancements in surgical robotic technologies.

By Graft Type, Saphenous Vein Grafts Segment Dominates the Market

In 2025, the market share of Saphenous Vein Grafts (SVG) was 46.68%, due to their easy accessibility, various benefits, and long history of use in clinical practice for CABG. These grafts are particularly useful in the setting of multiple bypasses, with over 720,000 procedures with SVGs in 2025.

Radial Artery Grafts are projected to see the highest growth of 4.19% CAGR through 2023 due to better long-term patency rates, surgeon preference of arterial grafting for CABG, and better patient outcomes.

By Device / Product Type, Cardiopulmonary Bypass Machines Segment Dominates the Market

In 2025, Cardiopulmonary Bypass Machines accounted for the largest share of 31.57%. These machines were depended on for CABG surgeries totaling more than 610,000 in 2025, leading to persistent demand.

Endoscopic Vessel Harvesting Systems are anticipated to grow at the fastest 4.66% CAGR during the forecast period, owing to the transition towards minimally invasive procedures that help in reducing surgical trauma and improving recovery times

By End-User, Hospitals Segment Dominates the Coronary Artery Bypass Graft Market

The largest market share of 68.82% in 2025 was held by hospitals, due to the presence of the sophisticated surgical infrastructure, skilled cardiac surgeons, and intensive care units needed to perform intricate bypass surgeries. Over 1.1 million Coronary-Artery Bypass Graft (CABG) procedures were done as inpatient admissions in 2025.

The Ambulatory Surgical Centers (ASCs) segment is expected to attain the highest CAGR of 4.73%, due to the growing demand for affordable treatment options, reduced hospital stay, and advancements in outpatient cardiac care.

Do you have any specific queries or need any customization research on Coronary Artery Bypass Graft Market, make an Enquiry Now: https://www.snsinsider.com/enquiry/10094

Coronary Artery Bypass Graft Market Key Segments

By Procedure / Technology Type

• On-Pump CABG (Conventional)
• Off-Pump CABG (Beating Heart Surgery)
• Minimally Invasive Direct CABG (MIDCAB)
• Robotic-Assisted CABG

By Graft Type (Conduit Type)

• Saphenous Vein Grafts (SVG)
• Internal Mammary / Thoracic Artery Grafts
• Radial Artery Grafts
• Other / Composite Grafts

By Device / Product Type

• Cardiopulmonary Bypass Machines
• Heart Stabilizers & Positioning Systems
• Anastomosis & Suturing Devices
• Cannulas & Tubing Sets
• Endoscopic Vessel Harvesting Systems

By End User

• Hospitals
• Cardiac Specialty Centers
• Ambulatory Surgical Centers (ASCs)

North America Dominates the Coronary Artery Bypass Graft Market, Asia-Pacific to Register Fastest Growth

The market share of North America was USD 38.64% in the year 2025, being supported by the advanced surgical methods, high surgical volumes, and lucrative health care infrastructure. This region also has high levels of spending on healthcare, a rising aged population, and high rates of coronary artery disease.

Asia-Pacific is expected to be the fastest growing region over the forecast period, with a CAGR of 4.79% due to the favorable healthcare infrastructure, increasing awareness regarding cardiac treatments, and the growing accessibility of procedures in countries like China, India, and Japan. The other is from medical tourism for more positive treatment expenses in the region.

Recent Developments

• In September 2025, Medtronic plc expanded its cardiac surgery portfolio with advanced cardiopulmonary bypass and perfusion systems, enhancing efficiency and safety in CABG procedures and supporting high-volume cardiac surgery centers.

• In July 2025, Boston Scientific Corporation introduced enhancements in surgical support and cardiovascular intervention technologies, improving integration between interventional cardiology and surgical workflows, indirectly strengthening CABG procedure planning and outcomes.
• In June 2025, Abbott Laboratories advanced its cardiovascular surgical support technologies and imaging systems, improving intraoperative visualization and precision in complex coronary procedures, including CABG, thereby supporting better clinical outcomes and surgical decision-making.

Buy an Enterprise-User PDF of Coronary Artery Bypass Graft Market Outlook Report 2026-2035: https://www.snsinsider.com/checkout/10094

Coronary Artery Bypass Graft Market Report Scope

Related Market Reports

Coronary Stent Market

Cardiac Catheters and Guidewires Market

Cardiac Rhythm Management Devices Market

Cardiac Assist Devices Market

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

CONTACT: Contact Us: Rohan Jadhav - Principal Consultant Phone: +1-315-961-9094 (US) Email: info@snsinsider.com 

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.

Delray Beach, FL, May 05, 2026 (GLOBE NEWSWIRE) — The global sleep apnea devices market was valued at USD 6.47 billion in 2024 and reached USD 6.93 billion in 2025. It is expected to grow at a strong CAGR of 10.9% between 2025 and 2032, reaching approximately USD 11.61 billion by the end of the forecast period. This growth is driven by the increasing adoption of connected healthcare technologies, expanding presence in emerging markets, and a growing preference for cost-effective, home-based treatment solutions.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=719

Why Does Sleep Apnea Matter More Now?
Sleep apnea often underdiagnosed and closely linked to conditions such as cardiovascular disease and diabetes is gaining increasing attention from healthcare systems and corporate stakeholders. Its impact on overall health and workplace productivity has made it a growing concern worldwide. With advancements in telemedicine, mobile health, and artificial intelligence, both diagnosis and treatment approaches are rapidly evolving. As a result, the sleep apnea devices market is emerging as both a critical healthcare priority and a significant business opportunity.

What Is Driving Innovation and Investment in the Market?
Strong momentum in the sleep apnea devices market is being driven by continuous innovation and rising investments. Manufacturers are increasingly focusing on next-generation Continuous Positive Airway Pressure (CPAP) devices, improving comfort, usability, and patient adherence. These advancements are helping expand access globally while enhancing treatment outcomes.
At the same time, favorable reimbursement policies for remote patient monitoring and connected care solutions are making advanced therapies more accessible to a broader patient base. In addition, rapid expansion into emerging markets such as India, Australia, United Arab Emirates, and Saudi Arabia is unlocking new growth avenues. Increasing healthcare infrastructure and awareness initiatives in these regions are further accelerating adoption.

What Challenges Are Limiting Market Growth?
Despite strong growth prospects, the market continues to face several challenges. Diagnostic delays, limited patient awareness, and gaps in referral pathways remain key bottlenecks. Additionally, adherence to CPAP therapy is often low due to discomfort and insufficient patient education. Addressing these issues presents an opportunity for healthcare providers and device manufacturers to differentiate themselves through improved patient training, support programs, and more user-friendly device designs.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=719

Why Is Home Healthcare Becoming a Major Opportunity?
Rising healthcare costs and increasing patient preference for convenience are accelerating the shift toward home-based solutions such as home sleep apnea tests (HSATs) and at-home therapies. Enabled by wireless connectivity, smartphone integration, and real-time monitoring, these solutions are transforming patient engagement. They also provide a scalable and cost-effective care model, allowing healthcare providers to deliver continuous monitoring and personalized treatment outside traditional clinical settings.

How Is the Market Segmented and Where Is Growth Concentrated?
The sleep apnea devices market is segmented across product type, end users, and regions, each showing distinct growth dynamics.

By product, Positive Airway Pressure (PAP) devices continue to dominate the therapeutic segment, driven by improvements in portability, noise reduction, and user comfort.

By end user, homecare settings accounted for the largest share in 2024, reflecting the broader shift toward decentralized and patient-centric healthcare. Meanwhile, sleep labs and clinics are also expanding due to advancements in diagnostic infrastructure.

Regionally, North America leads the market in terms of share, while Asia Pacific is expected to witness the fastest growth, supported by a rising burden of comorbidities, a large pool of undiagnosed patients, and increasing healthcare investments.

Who Are the Key Industry Players and What Are Their Strategies?
The competitive landscape is led by major players such as ResMed, Koninklijke Philips N.V., and Fisher & Paykel Healthcare. These companies are strengthening their market positions through continuous product innovation, strategic acquisitions, and geographic expansion.

ResMed maintains a leadership position through innovations like the AirFit F40 ultra-compact mask and expansion of manufacturing capabilities in Asia Pacific. Koninklijke Philips N.V. is enhancing accessibility through partnerships and acquisitions, particularly in underserved markets. Meanwhile, Fisher & Paykel Healthcare focuses on advanced humidification systems and mask technologies to improve patient comfort and adherence.

Other notable players shaping the market include Inspire Medical Systems, SomnoMed, Compumedics, Löwenstein Medical, Drive DeVilbiss, BMC Medical, and Nihon Kohden.

What Are the Latest Industry Developments?
Recent developments highlight strong innovation and strategic activity within the market. In June 2024, ResMed launched the AirFit F40, a compact full-face mask designed to improve patient compliance. In April 2024, Fisher & Paykel Healthcare introduced Autofit nasal and pillow masks in the US market. In May 2024, DynaFlex acquired Whole You, Inc., strengthening its position in oral appliance therapy. Earlier, in November 2022, ResMed established a large-scale advanced manufacturing hub in Singapore.

What Is the Strategic Outlook for the Market?
The sleep apnea devices market is entering a pivotal phase of transformation. With the rapid adoption of AI-enabled diagnostics, connected care solutions, and home-based therapies, stakeholders across healthcare systems, insurance providers, and corporate sectors are presented with new opportunities. These include reducing healthcare costs, enhancing workforce productivity, and improving patient outcomes. For decision-makers, this evolution represents more than a healthcare trend it signals a broader business transformation impacting risk management, employee wellness, and long-term value creation.

For more information, Inquire Now!

Discover Connected Healthcare Market Opportunities:
Sleep Apnea Oral Appliances Market
Anti-snoring Devices Market
Respiratory Care Devices Market
Ventilators Market
Patient Monitoring Devices Market

Get access to the latest updates on Top Companies in Sleep Apnea Devices and Sleep Apnea Devices Market Size

CONTACT: About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook . Contact: Mr. Rohan Salgarkar MarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 USA: +1-888-600-6441 Email: sales@marketsandmarkets.com Visit Our Website: https://www.marketsandmarkets.com/

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.

JETEX EXPANDS ITS GLOBAL REACH WITH A LANDMARK TERMINAL IN ISTANBUL

JETEX EXPANDS ITS GLOBAL REACH WITH A LANDMARK TERMINAL IN ISTANBUL

Dubai, May 05, 2026 (GLOBE NEWSWIRE) — Jetex, the world’s favorite private aviation brand, and İGA Istanbul Airport, a global leader in aviation connectivity, have inaugurated the Jetex İGA Terminal.

The landmark terminal is designed to welcome international commercial airline passengers and private jet travelers, merging the global expertise of Jetex with İGA’s operational strength and the warmth of Türkiye’s hospitality.

“We are thrilled to expand our global network with the launch of Jetex Istanbul alongside our valued partner İGA. Istanbul is a multicultural hub where thousands of years of history and culture blend with youthful, dynamic energy. We have put tremendous effort into crafting a state-of-the-art experience for both private jet and commercial airline travelers, and we look forward to welcoming the world here with award-winning Jetex hospitality,” said Adel Mardini, Founder & CEO of Jetex.

İGA Chairman Cemal Kalyoncu underscored the airport’s role as a global gateway: “İGA Istanbul Airport today connects over 340 destinations across more than 140 countries, and this leadership continues to attract new investments and an ever-expanding range of services.”

The terminal’s architecture draws inspiration from Istanbul’s iconic nazende çiçeği (slender flower), featuring natural stone, wood and custom-crafted surfaces that create a distinctive and comfortable travel environment.

Far more than a transit point, the terminal offers a private members’ club atmosphere with seamless, personalized service covering every step of the journey – before, after or between the flights.

For the first time, the award-winning Jetex hospitality is complemented by a selection of spa treatments along with exquisite hotel-inspired private suites for utmost comfort.

Highlights include:
– Private suites featuring relaxation areas, dining spaces, en-suite bathrooms and dedicated service teams;
–  Luxurious lounges, enhanced duty free retail and open-air terraces;
–  Expedited passport and security formalities through dedicated checkpoints.

The facility caters to both commercial airline passengers and private jet travelers by reservation. Guests also benefit from a chauffeur-driven luxury fleet of cars for their airside as well as city transfers.

Attachments

• JETEX EXPANDS ITS GLOBAL REACH WITH A LANDMARK TERMINAL IN ISTANBUL
• JETEX EXPANDS ITS GLOBAL REACH WITH A LANDMARK TERMINAL IN ISTANBUL

CONTACT: Oleg Kafarov Jetex 042124900 teamorange@jetex.com 

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.

The market for sports technology is rich in opportunities across the burgeoning use of AI, IoT, and big data across performance analysis, fan interaction, and sport management. Smart wearables, virtual and augmented reality, and AI-based coaching solutions are revolutionizing training and game plans for athletes.

Download PDF Brochure:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=104958738

Major Key Players in the Sports Technology Industry:

• Apple Inc. (US),
• SAMSUNG (South Korea),
• Alphabet Inc. (US),
•  Cisco Systems, Inc. (US),
• IBM (US),
• Telefonaktiebolaget LM Ericsson (Sweden),
• Catapult (Australia),
• Garmin Ltd. (US),
• Johnson Controls (Ireland), and
• Schneider Electric (France) among others.

Sports Technology Market Segmentation:

Wristwear in wearables to hold high market share in the technology segment in the sports technology market.

Wristwear like smartwatches and fitness trackers are a prominent wearable technology, which combines timekeeping with enhanced connectivity features. With wireless and Bluetooth integration, they expand the functionality of smartphones, allowing people to receive calls, read messages, get weather forecasts, and control media. Market leaders such as Fitbit Inc. (US) and Apple Inc. (US) included top-level health sensors in their offerings, so users can measure important health variables such as heart rate, burnt calories, and walked steps. As they play an increasingly key role in contactless payments, smartwatches include NFC and RFID chips that allow transactions by barcode and QR code scanning. Samsung Electronics Co., Ltd. (South Korea), LG Electronics Inc. (South Korea), Sony Corporation (Japan), and Garmin Ltd. (US) are key players in the market, leading innovation and accessibility. Apple Inc. (US) released the Apple Watch Series 10 in September 2024, with an improved design, a sophisticated display, and new features such as sleep apnea alerts, quicker charging, and water depth sensing. The watch, which comes in aluminum and titanium finishes, uses the S10 SIP for greater performance and efficiency. In July 2024, Samsung Electronics (South Korea) also launched the Galaxy Watch Ultra, Watch7, and Watch FE series, which use Wear OS 5. These trackers use sensors such as accelerometers and optical heart rate sensors to gather real-time data. They also have compatibility with mobile phone apps such that the user can monitor progress and define fitness objectives. Google Inc. (US), Garmin Ltd. (US), and Apple Inc. (US) regulate the fitness trackers market through their advanced product offerings. Xiaomi Corp. (China) controls the affordable fitness wearables market, and Samsung Electronics (South Korea) offers fitness functionalities within its series of smartwatches.

AI-based segment is projected to grow at a high CAGR of sports technology market during the forecast period.

Solutions powered by AI are transforming training for athletes through machine learning and predictive analytics to evaluate biomechanics, track fatigue levels, and create injury prevention programs. Such systems process huge sets of player information, giving the coaches valuable inputs to make finer game strategies, better decision-making, and performance as a unit. AI also revolutionizes sport broadcasting and supporter interaction through serving hyper-personalized content, automated highlights, and interactive interactions. AI-camera systems monitor movement of players and maximize live steaming angles using AI, with computer vision utilized for automatic annotation of highlights of the action, instant replay production. Apart from these, AI chatbots and virtual assistants enrich fans’ interactions by offering them timely updates, statistics of the players, and game insights as per their interest.  Increased uptake of AI at smart stadiums further fuels the growth of the market, with the use of AI-based solutions improving security, managing crowds, and cashless transactions. The uses of AI for esports and training in virtual sports are also spreading, with solutions providing AI-fabricated simulation and feedback during play. With the continued growth in AI, its application in different aspects of sports technology will fuel innovation, improve competitive performance, and reshape the digital transformation.

Soccer in the sports technology market to hold the highest market share during the forecast period.

Soccer will be expected to possess the largest market share in the sports technology market during the forecast period owing to its immense global fan base, increasing investments in digital transformation, and implementation of advanced analytics and wearable technologies. As the world’s favorite sport to watch and play, soccer clubs and associations are adopting the latest technologies to enhance the performance of players, simplify game strategy, and provide a better experience for fans. Artificial intelligence-powered video analysis and computer vision technologies are transforming match analysis so that coaches can analyze player position, ball tracking, and tactics with unprecedented accuracy. Wearable devices like GPS and biometric sensors are fast becoming a prerequisite for tracking the health, workload, and prevention of injuries for players. Increasingly, national teams and clubs are using them to track endurance, acceleration, and fatigue, optimizing player performance and recovery control. Improvements in smart stadium and digital broadcasting technology are also enhancing the fan experience, as AI cameras, AR/VR applications, and fan engagement platforms enhance the viewing experience.

Sports associations end-user to hold high market share during the forecast period.

Sports associations play a crucial role in deciding the evolution, regulation, and promotion of sports at regional and international levels. Sporting associations govern sport regulations, schedule matches, and control the welfare of players. With technology constantly innovating the sporting industry, collaboration between technology firms. Sports associations are increasing, which is generating high-speed innovation in player performance, team administration, and interaction with fans. National authorities, e.g., BCCI in cricket or FIFA for football, are now more often adopting advanced technologies to advance playing strategies, streamline officiating for higher accuracy, and enhance the overall efficiency of operations.  Among the dominant sectors of integration is performance analysis, where data platforms based on artificial intelligence and wearable tracking hardware are assisting squads to track movements of players, biomechanics, and areas of injury in real time.  Furthermore, the partnerships between sports leagues and technology companies are driving data-led decision-making, enabling leagues and teams to maximize recruitment activity, marketing activity, and sponsorships. With ongoing partnerships, sport technology will be a key element in the growth of the industry, generating competitive advantages and wealthier international sport experiences.

Ask for Sample Report:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=104958738

Asia Pacific will account for the highest CAGR during the forecast period.

Asia Pacific will record the highest CAGR in the sports technology market throughout the forecast period, led by accelerating digital transformation, growing sports infrastructure investments, and growing use of advanced analytics, AI, and IoT-based solutions. China, India, Japan, and South Korea are among the nations that are experiencing tremendous growth in professional sports leagues, and consequently, there is a high demand for performance-enhancing technologies, intelligent stadiums, and interactive fan engagement solutions. Governments and private organizations are making heavy investments in sports technology to enhance training methodologies, increase athlete performance, and enhance the overall sports ecosystem. The surge in popularity of wearable technology and intelligent fitness solutions is also driving market growth in the region. Athletes and sports enthusiasts are adopting AI-powered wearables to track performance in real-time, biometrics, and avoid injuries. The explosive growth of virtual sports and esports platforms is creating new revenue streams, with the Asia Pacific region emerging as a global hub for competitive gaming and virtual sports experience. The deployment of 5G networks and developments in cloud computing are also enabling seamless processing of real-time data, further strengthening the capability of AI-based sports analytics. As sports authorities, technology companies, and broadcasters collaborate to create future-ready solutions, the Asia Pacific market for sports technology will witness massive growth, turning the region into a center for sports innovation in the world.

Key Takeaways:

• The North American sports technology market share accounted for a 33.0% revenue share in 2024. This strong market position highlights the region’s advanced adoption of analytics, AI-driven performance tools, and digital fan engagement technologies.
• By technology, the stadium analytics segment is projected to register the highest CAGR of 17.2%.
• By platform, the AI-based platform segment is projected to grow at the fastest rate from 2025 to 2030.
• Sport technology in Formula 1 is set to grow at the highest CAGR of 16.8% during the forecast period.
• The Sports Associations are estimated to hold almost half the share in 2025, supported by increasing investments in smart stadiums, the growth of AI-driven analytics, and the adoption of fan engagement technologies.
• Apple Inc., Catapult, and Samsung were identified as some of the star players in the wearable segment of the sports technology market trends, given their strong market share and product footprint.

See More Latest Semiconductor Reports:

Augmented and Virtual Reality Market by HMD, HUD, Gesture Tracking Device, Projector & Display Wall, Non-immersive, Semi & Fully Immersive, Markerless AR, Anchor-Based AR, Marker-Based AR, Application (Consumer, Commercial) – Global Forecast to 2032

Building Automation System Market Size, Share & Trends by Facility Management Systems, Security & Access Control, Fire Protection Systems, Building Energy Management Software, Building Automation System Services, Residential, Industrial, Commercial – Global Forecast to 2030

CONTACT: About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook . Contact: Mr. Rohan Salgarkar MarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 USA: +1-888-600-6441 Email: sales@marketsandmarkets.com Visit Our Website: https://www.marketsandmarkets.com/

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.

HONG KONG, May 05, 2026 (GLOBE NEWSWIRE) — MCG Limited today issued a formal statement on behalf of Mr. Ken Lai, Founder of MCG Limited and former Chief Executive Officer of Brandoville Studio, to provide a factual update regarding the studio’s closure and to address recent misinformation circulating online.

Factual Context of Studio Closure

The statement confirms that Brandoville Studio officially ceased its operations on July 28, 2024. This business decision was the result of commercial disagreements between shareholders regarding the company’s future strategic direction. Following the closure, Mr. Lai relocated back to Hong Kong. It was approximately one and a half months later (mid-September 2024) that he was made aware of these subsequent online reports. He was extremely shocked and saddened by these allegations, as these discussions emerged well after the studio’s operations had completely concluded. These localized discussions subsequently subsided, only to be unexpectedly resurfaced and sensationalized by content creators on video-sharing platforms in 2025.

Clarification on Workplace Environment

Regarding recent online discussions concerning the studio’s workplace environment during its active years, MCG Limited clarifies the following facts:

Absence of Internal Grievances:

During the studio’s operational period prior to its closure, the management team did not receive formal complaints or claims from employees regarding workplace misconduct or exploitation.

Current Status:

To the company’s best knowledge, there are no formal legal proceedings, criminal charges, or official regulatory investigations initiated against the studio’s management regarding these claims.

Commitment to Professional Standards

MCG Limited and Mr. Lai remain steadfast in their commitment to upholding the highest levels of professional integrity and ensuring comprehensive safeguarding for all employees.

About MCG Limited

MCG Limited is a private holding company founded by Ken Lai, responsible for managing his various investments and business affairs. This statement is issued to provide an accurate, fact-based account regarding recent corporate matters.

Media Contact:
Corporate Communications Department
MCG Limited
Email: hanwoo@mcglimited.hk

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/222ab429-940c-48bc-bfce-c90d8242073b

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.

What Causes Lower Back Pain in Daily Life

Lower back discomfort is becoming a routine part of modern life, often developing gradually rather than from a single injury. For many adults, it tends to build over time through everyday routines such as long hours at a desk, repeated lifting, or standing for extended periods without proper support.

The impact varies by daily routine. Office workers may feel stiffness after hours at a desk, while manual laborers often deal with strain from repetitive tasks. Even active individuals and fitness enthusiasts can experience discomfort tied to posture or overuse.

As these small stresses accumulate, the need becomes less about short-term relief and more about consistent, reliable support that fits into daily routines without limiting movement.

How a Back Brace Helps Relieve Lower Back Pain and Improve Posture

As lower back discomfort becomes part of daily routines, effective support often comes down to one key factor: how well the body is supported under pressure. When the lower back is repeatedly strained, whether from sitting, lifting, or physical activity, it benefits from added structure that helps stabilize the area and maintain proper alignment.

The design of a back brace plays a key role in how effectively it supports the lower back. The FEATOL Back Brace Support Belt uses four reinforced support strips along with an additional lumbar pad to create a more balanced level of support across the lower back. This structure helps distribute pressure more evenly, which can make it easier to maintain proper posture during daily movement.

For support to be used consistently, comfort matters just as much as stability. Materials that trap heat or feel bulky can make extended wear difficult over time. With this in mind, the FEATOL Back Brace Support Belt uses breathable materials to make extended wear more comfortable. The inner elastic neoprene layer offers gentle support while still allowing the body to move naturally. The adjustable outer band, secured with a hook-and-loop closure, makes it easy to find a fit that feels comfortable and stays in place without feeling too tight.

What Users Notice With Daily Back Brace Support

User feedback around the FEATOL Back Brace Support Belt suggests that consistent wear can make a noticeable difference over time. Some users report feeling less lower back strain by the end of the day, particularly after long hours of sitting or standing, while others note that the support feels stable without feeling restrictive once properly adjusted.

Overall, users are leaning toward support that can be worn throughout the day without disrupting routine. For those looking to explore daily back support options, more information on the FEATOL Back Brace Support Belt is available at https://featol.com/.

About FEATOL

FEATOL is a brand focused on premium protective braces and ergonomic support products designed for everyday use. Built on the belief that protection should not come at the cost of comfort or style, the company develops solutions for individuals managing pain, recovering from strain, or seeking preventative support in their daily routines.

Media contact

Contact Person: Lora

Email: info@featol.com

Website: featol.com

Photos accompanying this announcement are available at 

https://www.globenewswire.com/NewsRoom/AttachmentNg/b68de2c9-db44-424f-ba79-1b88cf5f3338

https://www.globenewswire.com/NewsRoom/AttachmentNg/e5ec109a-fc5c-405f-a201-10a3cf2560b3

https://www.globenewswire.com/NewsRoom/AttachmentNg/c479ddca-9959-4824-90f7-b81b8049ea18

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.

Austin, May 05, 2026 (GLOBE NEWSWIRE) — The Travel Insurance Market size was valued at USD 30.53 Billion in 2025 and is projected to reach USD 148.14 Billion by 2035, growing at a CAGR of 17.11% during the forecast period.

Demand for travel insurance keeps developing across individual, corporate, and senior voyager sections with a rising openness to pandemic-related interruptions rising, cataclysmic events supporting fears of getting medical care abroad, and dangers of outing abrogation driving purchaser hunger for extensive financial assurance answers for both relaxation and business travel classes.

Download PDF Sample of Travel Insurance Market @ https://www.snsinsider.com/sample-request/8876 

The U.S. Travel Insurance Market is projected to grow from USD 5.76 Billion in 2025 to USD 26.96 Billion by 2035, at a CAGR of 16.69%.

The growth in the U.S. market is driven by increased frequency of travel from domestic and international destinations, greater awareness among consumers about medical and trip protection requirements, swift adoption of policies on the digital medium and an increase in protective purchasing for trips that cover cancellations, delays or emergencies during their travels.

Segmentation Analysis:

By Coverage

Medical Expenses accounted for the largest share of the coverage section with a value share of 39% in 2025 on the back of growing health care costs in foreign lands and rising medical emergencies among overseas travelers making it absolutely necessary to buy insurance that covers the cost of hospitalization, treatment, and emergency evacuations. Trip Cancellations will witness the highest CAGR of 19.37% during 2026-2035 due to growing awareness about the huge financial costs involved when a traveler’s journey gets canceled or interrupted because of pandemics, natural calamities, and other unpredictable situations.

By End User

Senior Citizens had the highest end user market share of 30%, which is mainly because of their increased vulnerability to health problems, coupled with their large number of needs for coverage of healthcare facilities, hospitalization, and evacuations while traveling overseas. The fastest CAGR during 2026–2035 will be experienced by Business Travelers, which is due to the growing globalization of business activities, with increased participation of companies in international meetings, conferences, and customer visits.

By Distribution Channel

Insurance Companies was the highest, at 30%, driven by its efficient network of distribution, quality products offered by them, competitive pricing, and reliability in the payment of claims that result in increased consumer acceptance than intermediaries. The growth in distribution through banks is forecasted to be the fastest at a CAGR of 19.37% until 2035, owing to the increasing partnerships between banks and travel insurance companies which benefit from large customer bases, trust in finance, and bundled offers such as travel loans and credit cards.

By Insurance Type

Single Trip Travel Insurance was leading the market share of around 59% in 2025 owing to its affordable nature, simple structure, and high attraction amongst part-time leisure travelers who were looking for flexible insurance coverage against medical issues, cancellation, and baggage loss during one trip only. Annual Multi-trip Travel Insurance is likely to show a high CAGR of 18.17% between 2025 and 2035 mainly because of increasing global movement amongst frequent corporate travelers and enthusiasts, who do not require buying policies for individual trips throughout the year.

If You Need Any Customization on Travel Insurance Market Report, Inquire Now @ https://www.snsinsider.com/enquiry/8876 

Regional Insights:

Europe dominated the global travel insurance market in 2025 with a 37% revenue share, supported by ever growing outbound tourism volumes, well-established travel infrastructure, obligatory insurance coverage mandatory across some European countries, a high proportion of aging population necessitating increased medical coverage and facilitated contracts between insurers and airline & travel agencies that promote general availability throughout the regional landscape.

The regional market in Asia Pacific is anticipated to grow at the fastest rate, with a CAGR of 18.70% until 2035, fueled by increasing disposable incomes along with growing middle-class populations and outbound tourism and business travel across China, India and Southeast Asian countries. Rising consumer awareness of travel risks, emerging digital insurance platforms, and government welfare schemes to boost international tourism are together creating a strong structural demand landscape for travel insurance throughout the region.

Rising Global Tourism Volumes and Growing Exposure to Travel Disruptions Driving Structural Demand for Comprehensive Travel Insurance Coverage

One key structure influencing the development of the travel insurance market is that of international tourism recovery and growth along with business travel becoming more and more globalized. In 2023, the recovery and growth of international tourism is very significant, with the World Tourism Organization estimating there have been 1.3 billion international arrivals – roughly 89% of what it was prior to the pandemic. As disposable income increases, middle classes increase and international business opportunities become more common, travelers become increasingly vulnerable to being involved in medical emergencies, canceling trips, having their luggage stolen or lost and accidents overseas. To address these new trends in travel insurance, companies offer various types of plans, including multi-trip plans, special plans for seniors and adventure activities.

Key Players:

• Allianz
• American International Group, Inc.
• AXA
• Assicurazioni Generali S.p.A.
• USI Insurance Services, LLC
• battleface
• Insure & Go Insurance Services Limited
• Seven Corners Inc.
• Travel Insured International
• Zurich
• Delphi Financial Group, Inc.
• Ping An Insurance (Group) Company of China, Ltd.
• Berkshire Hathaway Travel Protection (BHTP)
• Chubb
• World Nomads
• Tokio Marine HCC
• International Medical Group (IMG)
• Travelex Insurance Services
• Trawick International
• Ingle International

Buy Full Research Report on Travel Insurance Market 2026-2035 @ https://www.snsinsider.com/checkout/8876 

Recent Developments:

In 2025, Allianz Partners expanded its Vacation Confidence Index to span the USA, Europe, and Asia Pacific, tracking traveler intent and behavior trends across major markets to shape strategic innovation in its travel insurance product development and customer engagement programs.

In 2024, Allianz Partners announced a long-term extension of its partnership with Iberia, continuing as the airline’s global travel insurance provider across 13 markets and reinforcing the growing strategic importance of airline-integrated insurance distribution as a key channel for seamless policy access during flight bookings.

In 2024, World Nomads launched its Annual Multi-Trip policy across the UK and Ireland through Collinson underwriting, featuring children’s coverage, age extensions, and SmartDelay airport delay benefits — reflecting the market’s accelerating shift toward comprehensive multi-trip formats serving frequent international travelers.

Read Other Related Reports:

Insurance Analytics Market

Insurtech Market

Insurance Telematics Market

Commercial Insurance Market

AI in Insurance Market

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

CONTACT: Rohan Jadhav - Principal Consultant Phone: +1-315-961-9094 (US)

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.

Ms. Phua Mei Ming, Chief Executive Officer of HomesToLife, said, “Mr Chai has been a key member of our leadership team, and his deep financial expertise and operational experience will be instrumental as we continue to scale the business. As we move forward, we remain focused on executing our expansion strategy, strengthening our presence in key markets, and positioning HomesToLife to capture new growth opportunities.”

The Company believes that Mr. Chai brings extensive experience in finance, operations, and strategic leadership across the furniture and manufacturing sectors. He served as Chief Financial Officer and Secretary of HTL Furniture Inc., a U.S.-based related party of the Company, since September 2020, and was also Regional Vice President of Finance for several subsidiaries of the Company. Prior to this, Mr. Chai held the position of Vice President of Finance and Operations at HTL Furniture Inc. from September 2020 to December 2023.

Mr. Chai holds a Bachelor of Science in Accountancy and a Master of Business Administration from Boise State University, as well as a Bachelor of Engineering in International Business and Automatic Control Engineering from Shanghai Jiao Tong University. He is a licensed Certified Public Accountant.

About HomesToLife Ltd (Nasdaq: HTLM)

HomesToLife Ltd is a global furniture company with three core divisions: (i) export division for supplying furniture to retail partners worldwide, (ii) leather trading division, and (iii) consumer retail division with direct operations in Singapore and Korea.

Leveraging more than 50 years of heritage built by its founders, the Company combines retail, distribution, and sourcing, supported by a diversified manufacturing network across China, Vietnam, and India.

In May 2025, the Company strengthened its design, product development and merchandising function through the acquisition of HTL Marketing.

The Company is fast expanding across Europe, Asia-Pacific, and North America, leveraging long-standing supplier partnerships and a global presence to deliver scale, efficiency, and resilience.

Contacts

HomesToLife Ltd Contact:

6 Raffles Boulevard, #02-01/02
Marina Square, Singapore 039594
Email: Investor@homestolife.com

Investor Relations Inquiries:

Edelman Smithfield
Jass Lim, Enya Rodrigues
HomesToLife@edelmansmithfield.com

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.

To our shareholders,

This letter is intended to provide a clear update on where the business stands and what we are focused on next.

I write to you from a unique vantage point: as a founder who has spent seven years building Cyabra’s foundation, as a fellow shareholder whose interests are directly aligned with yours, and as a CEO dedicated to translating our operational momentum into measurable value for our stockholders.

The first month as a public company

Cyabra completed its de-SPAC transaction and began trading on March 27, 2026 and leading up to the completion of the transaction and since closing, we have successfully capitalized on a number of growth opportunities, as previously announced, such as:

What Cyabra is?

Cyabra is a digital trust platform. We help institutions distinguish authentic activity from coordinated manipulation across public digital channels. Our framework is built around three layers — the actors involved, the behaviors they exhibit, and the content they amplify — and our platform translates that analysis into structured evidence and clear mitigation steps. We surface evidence and institutions retain judgment. That distinction is deliberate, and it is the basis for how sovereign and enterprise customers integrate our work into their own decision-making.

Why institutions choose Cyabra

The clearest evidence of the success of our platform is the institutions that have chosen to work with us. Cyabra has been engaged by NATO and Korea’s Ministry of Foreign Affairs in the public sector, and by global enterprises, including PepsiCo, e.l.f. Beauty, and IPG. In 2022, Cyabra was commissioned to provide independent analysis during what became the most-watched corporate transaction of the decade — Elon Musk’s acquisition of Twitter — and our findings were cited globally across more than 11,000 media reports. That body of work, accumulated over years, is what allows a company at our current scale to operate alongside organizations many multiples our size.

On April 14, 2026, we announced an expanded two-year renewal with a global entertainment management firm, valued in the six figures. The renewal broadened the scope of our services to include real-time narrative and authenticity analysis, proactive threat alerts, and enhanced monitoring for impersonation and AI-generated content. This kind of expansion — existing customers choosing to deepen their use of our platform — is the form of growth we believe matters most for a recurring-revenue business.

Governance and the operational reach behind our customer base

Cyabra’s access to sovereign customers and Fortune 100 enterprises does not happen by accident at our scale. It is supported by the operational reach of our Board of Directors and Advisory Board, which together combine deep experience across national security, intelligence, government operations, global enterprise, and strategic communications.

Our Board includes Mike Pompeo (former U.S. Secretary of State and former Director of the Central Intelligence Agency), Josette Sheeran (Capital Group, World Economic Forum, former U.S. Ambassador), James Flanagan (former COO of PwC), Sonny Vu (founder of Misfit), and Michael Madon (Chief Revenue Officer of ABCorp and former senior leader at Mimecast and the U.S. Treasury intelligence community).

We treat this as one of the most important assets we have as a company at this stage. It is also part of why we believe in the durability of our customer relationships and the credibility of our institutional pipeline.

Financial foundation

Our revenue has grown from $1.92 million in 2023 to $4.16 million in 2024 to $5.70 million in 2025. We believe our gross margin profile is strong and supports the unit economics of a recurring-revenue platform business. 2025 was a year of operational scaling — including extensive preparation for the public listing we completed in March 2026 — and we exited the year with a customer base, a margin profile, and a pipeline that we believe support the growth we expect ahead.

We will report formal Q1 2026 results later in May.

What we are focused on

As a public company, our work over the next several quarters is structured around five priorities:

Looking ahead

In the coming quarters, we expect to share progress across commercial expansion, product development, partnership initiatives, and governance milestones. We intend for the cadence and substance of our communication to reflect the standard public shareholders are entitled to expect from a newly listed company.

Closing

We are early in our life as a public company. The task in front of us is clear: execute with discipline, expand recurring revenue, deepen customer relationships, and communicate progress with the transparency public shareholders are entitled to expect. We believe Cyabra is building in a market that will become increasingly important to governments, enterprises, and the institutions that depend on a coherent picture of digital activity. Our responsibility is to prove that through results.

Thank you for your continued support.

Sincerely,

Dan Brahmy
Co-Founder and Chief Executive Officer
Cyabra, Inc.

About Cyabra

Cyabra helps global enterprises and governments restore trust and authenticity online by analyzing manipulated content, coordinated behaviors, and inauthentic actors. The platform helps teams understand who is operating, how activity is amplified, and where coordinated activity is shaping perception, translating evidence into clear mitigation steps. By reducing ambiguity and misdirected response, Cyabra enables proportionate, evidence-led action when clarity matters most.

For more information, visit www.cyabra.com.

Contact:

Investors: ir@cyabra.com

Media: pr@cyabra.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical statements of fact and statements regarding Cyabra’s intent, belief, or expectations, including, but not limited to, statements regarding Cyabra’s future results of operations and financial position, planned products and services, business strategy and plans, market size and growth opportunities, competitive position and market trends. Some of these forward-looking statements can be identified by the use of forward-looking words, including “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “plan,” “targets,” “projects,” “could,” “would,” “continue,” “forecast” or the negatives of these terms or variations of them or similar expressions. These statements relate to future events and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in Cyabra’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. Cyabra undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.

CHICAGO, May 05, 2026 (GLOBE NEWSWIRE) — MathCo, a global enterprise AI leader, today announced its collaboration with Google Cloud to help enterprises move toward workflow-native AI, a fundamental shift in how organizations build, scale, and realize value from artificial intelligence.

A Deloitte report, State of AI in the Enterprise, 2026, states that 66% of organizations report productivity gains from AI, yet only 34% are truly reimagining their business with it. For nearly three-quarters of enterprises, revenue growth from AI remains aspirational. This highlights the growing gap between AI activity and real business outcomes.

Anchored in MathCo’s proprietary concept of Systemic AI, the collaboration will leverage the full Gemini Enterprise ecosystem, including Gemini Enterprise Agent Platform and enterprise data connectivity, to help organizations build workflow-native AI systems.

Aakarsh Kishore, Chief Product Officer, MathCo, said, “We are excited that this collaboration comes at a stage when enterprises are truly looking at scaling. We are not just going to implement – we will advise our customers on the right use cases, how to build the right data and AI foundation, and how to sequence their journey to extract compounding value from every AI investment they make.”

Gemini Enterprise serves as the central AI platform for the enterprise, bringing together models, agents, data, and tools into a single, secure environment where workflows can be designed, executed, and scaled.

MathCo extends this by embedding Gemini Enterprise layers into a systemic architecture, ensuring intelligence is not applied to isolated tasks but orchestrated across workflows to deliver measurable business outcomes.

From Tasks to Workflows: Operationalizing Systemic AI on Gemini Enterprise

MathCo’s Systemic AI framework enables enterprises to move from action-oriented AI to outcome-driven systems, structured across four interconnected layers:

• Value Layer: Where AI is applied to redesign end-to-end business processes not just automate individual tasks.
• Intelligence Layer: Enabled by Gemini models, enterprise agents that can reason, plan, and execute across multi-step workflows.
• Foundation Layer: A unified enterprise knowledge layer integrating data, KPIs, workflows, and business rules that ensures every AI decision is grounded in business reality.
• Governance Layer: Providing control, observability, and feedback loops to ensure AI systems remain aligned with enterprise goals.

Built on Gemini Enterprise, designed to create, run, and orchestrate AI agents across workflows, this approach enables enterprises to connect intelligence across systems, teams, and decisions.

From AI Activity to Industry Outcomes

The collaboration will enable workflow-native transformation across industries and business functions, connecting intelligence across planning, decisioning, and execution.

In Retail, enterprises can build end-to-end merchandising intelligence where demand forecasting, assortment planning, pricing, and replenishment are orchestrated into a unified workflow, reducing stockouts and improving margins.

In CPG, trade promotion workflows move from fragmented planning to closed-loop systems by connecting promotion design, real-time sell-out monitoring, and ROI measurement, enabling dynamic optimization of trade spend.

In Pharma & Life Sciences, intelligent HCP engagement workflows connect content creation, medical-legal approval, deployment, and performance tracking by ensuring compliant, end-to-end engagement with continuous learning.

As enterprises navigate increasing AI complexity, with hundreds of tools, fragmented systems, and low adoption, the real challenge is no longer building AI, but making AI work cohesively within the enterprise and its people.

MathCo aims to address this by shifting the focus from isolated AI usage to AI that works across workflows, and works for people to augment decision-making while enabling teams to operate with intelligence at scale.

To learn more about MathCo’s Systemic AI approach, click here.

About MathCo

MathCo is a global Enterprise AI and Analytics company, trusted for data-driven decision making, by some of the largest organizations across industries. Founded in 2016, MathCo builds custom data products through its innovative hybrid model and transfers the ownership of intellectual properties to its clients. NucliOS by MathCo, enables the vision of connected intelligence at a lower TCO by leveraging pre-built workflows and reusable plug-and-play modules. MathCo’s full-stack team provides a holistic range of services spanning strategy, advanced analytics, data engineering, data governance, MLOps, GenAI, data visualization, and adoption advisory services. MathCo’s numerous accolades include recognition in Gartner’s Magic Quadrant for D & A Providers, Everest Group’s Peak Matrix Assessment, and being listed as a Great Place to Work. To know more about how MathCo supports organizations to own and activate intelligence, click here.

Media Contact:  

Shubham Kishore 

Shubham.Kishore@mathco.com 

+91 7827680885

Disclaimer:  This content is provided by TheMathCompany Pvt Ltd.. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. This content is for informational purposes only and should not be considered financial, investment, or business advice. All investments carry inherent risks, including the potential loss of capital. Readers are strongly encouraged to conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Neither the media platform nor the publisher shall be held responsible for any inaccuracies, misrepresentations, or financial losses resulting from the use or reliance on the information in this press release. Speculate only with funds you can afford to lose. In the event of any legal claims or concerns regarding this article, we accept no liability or responsibility. Globenewswire does not endorse any content on this page.

Legal Disclaimer: This media platform provides the content of this article on an “as-is” basis, without warranties or representations of any kind, express or implied. We assume no responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained herein. Any complaints, copyright issues, or inquiries regarding this article should be directed to the content provider listed above.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d9e610a9-5d8b-48e9-9ea3-301a392774f4

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.